BACKGROUND:Intravenous glucose-insulin-potassium (GIK) may have a positive metabolic influence in patients with acute myocardial infarction (AMI) who receive reperfusion therapy. The objective of this randomized trial was to assess for the first time whether GIK improves myocardial salvage in patients with AMI. METHODS: The Reevaluation of Intensified Venous Metabolic Support for Acute Infarct Size Limitation (REVIVAL) trial is a randomized, open-label study conducted among 312 patients with AMI. Patients were randomly assigned to either the GIK therapy group (n = 155) or the control group (n = 157). All patients were intended to receive reperfusion treatment, which was given in all but 5 patients (1.6%). The primary end point of the study was salvage index, measured as the proportion of initial perfusion defect (acute technetium-99m sestamibi scintigraphy) salvaged by therapy (follow-up scintigraphy performed after 7 to 14 days). RESULTS: The primary end point of the study, the salvage index, was in median 0.50 (25th, 75th percentiles: 0.18, 0.87) in the GIK group and 0.48 (25th, 75th percentiles: 0.27, 0.78) in the control group (P =.96). By 6 months, the mortality rate was 5.8% in the GIK group and 6.4% in the control group (P =.85; relative risk, 0.92; 95% CI, 0.37 to 2.26). Subgroup analyses showed that GIK therapy was associated with increased salvage index only among diabetic patients (mean difference, 0.19; 95% CI, 0.01 to 0.37). CONCLUSIONS: The routine use of GIK therapy in patients with AMI is not associated with enhanced myocardial salvage. This therapy appears to improve myocardial salvage only among diabetic patients.
RCT Entities:
BACKGROUND: Intravenous glucose-insulin-potassium (GIK) may have a positive metabolic influence in patients with acute myocardial infarction (AMI) who receive reperfusion therapy. The objective of this randomized trial was to assess for the first time whether GIK improves myocardial salvage in patients with AMI. METHODS: The Reevaluation of Intensified Venous Metabolic Support for Acute Infarct Size Limitation (REVIVAL) trial is a randomized, open-label study conducted among 312 patients with AMI. Patients were randomly assigned to either the GIK therapy group (n = 155) or the control group (n = 157). All patients were intended to receive reperfusion treatment, which was given in all but 5 patients (1.6%). The primary end point of the study was salvage index, measured as the proportion of initial perfusion defect (acute technetium-99m sestamibi scintigraphy) salvaged by therapy (follow-up scintigraphy performed after 7 to 14 days). RESULTS: The primary end point of the study, the salvage index, was in median 0.50 (25th, 75th percentiles: 0.18, 0.87) in the GIK group and 0.48 (25th, 75th percentiles: 0.27, 0.78) in the control group (P =.96). By 6 months, the mortality rate was 5.8% in the GIK group and 6.4% in the control group (P =.85; relative risk, 0.92; 95% CI, 0.37 to 2.26). Subgroup analyses showed that GIK therapy was associated with increased salvage index only among diabeticpatients (mean difference, 0.19; 95% CI, 0.01 to 0.37). CONCLUSIONS: The routine use of GIK therapy in patients with AMI is not associated with enhanced myocardial salvage. This therapy appears to improve myocardial salvage only among diabeticpatients.
Authors: Michael A Puskarich; Michael S Runyon; Stephen Trzeciak; Jeffrey A Kline; Alan E Jones Journal: J Clin Pharmacol Date: 2009-05-05 Impact factor: 3.126
Authors: Iwan C C van der Horst; Jan Paul Ottervanger; Arnoud W J van 't Hof; Stoffer Reiffers; Kor Miedema; Jan C A Hoorntje; Jan-Henk E Dambrink; A T Marcel Gosselink; Maarten W N Nijsten; Harry Suryapranata; Menko-Jan de Boer; Felix Zijlstra Journal: BMC Med Date: 2005-06-02 Impact factor: 8.775
Authors: Anouk M Corstjens; Iwan C C van der Horst; Jan G Zijlstra; A B Johan Groeneveld; Felix Zijlstra; Jaap E Tulleken; Jack J M Ligtenberg Journal: Crit Care Date: 2006-06-27 Impact factor: 9.097
Authors: Iwan C C van der Horst; Maarten W N Nijsten; Mathijs Vogelzang; Felix Zijlstra Journal: Cardiovasc Diabetol Date: 2007-02-06 Impact factor: 9.951